Erik van den Berg, CEO of Memo Therapeutics, shares his insights about leadership in biopharma and how Memo is working to develop antibodies to transform the lives of patients with viral infections and cancer.
All content for BioBoss is the property of John Simboli and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Erik van den Berg, CEO of Memo Therapeutics, shares his insights about leadership in biopharma and how Memo is working to develop antibodies to transform the lives of patients with viral infections and cancer.
David Barmam, founder and CEO of Emendio Biotherapeutics, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Emendo is working to evolve traditional CRISPR tools and create new nucleases customized to any genetic disease.
BioBoss
Erik van den Berg, CEO of Memo Therapeutics, shares his insights about leadership in biopharma and how Memo is working to develop antibodies to transform the lives of patients with viral infections and cancer.
